• News
  • SAN DIEGO
  • Finance

Isis gains most in 5 years on analyst praise for novel drug

Isis Pharmaceuticals Inc. (Nasdaq: ISIS) rose the most in almost five years after Cowen & Co. analyst Eric Schmidt raised his rating to outperform from neutral based on an experimental therapy's likelihood of becoming a blockbuster.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
65.09
  5.54  
+ 9.30%
10,081,817,000
67.12
22.25

Insider Trade Data

Date Insider Shares Type Value
12/01/2014 O Neil, Patrick R 1,500 Sell $76,815
12/01/2014 O Neil, Patrick R 1,500 Exchange $10,875
12/01/2014 O Neil, Patrick R 1,500 Sell $76,815
12/01/2014 O Neil, Patrick R 1,500 Exchange $10,875
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!